Based on the above‐described body of evidence, we conducted a double‐blind, sham‐controlled trial to study the efficacy of DLPFC‐rTMS in the treatment of ID and explore the associated neural mechanisms. We hypothesized that (1) significant differences in PAC values would be observed in ID patients and GSC at baseline, (2) active rTMS treatment would modulate abnormal PAC values in ID patients, and (3) the enhancement of PAC values was significantly correlated with improvements in sleep quality.
